Prostate Cancer

TON - September 2013 Vol 6 No 8 published on September 23, 2013 in Noteworthy Numbers, Hematologic Cancers
Wayne Kuznar

As the second leading cause of cancer-related deaths among men in the United States, prostate cancer is expected to cause approximately 29,720 deaths during 2013.1 In recognition of National Prostate Cancer Awareness Month, let’s examine these prostate cancer statistics.

According to the Prostate Cancer Foundation, the average age at the time of prostate cancer diagnosis is 69 years. Moreover, 1
in 14 men between the ages of 60 and 69 years receive a prostate cancer diagnosis.2

Prostate cancer is less common in men younger than 40 years, with 1 in 10,000 men affected.2

Overall, approximately 238,590 men in the US will be diagnosed with prostate cancer in 2013.1

The American Cancer Society states that the ratio of men who will die from prostate cancer is 1:36.1

African American men in the US are almost 2.5 times as likely to die from prostate cancer as white men.3 The rate of prostate cancer is less in Asian American and Hispanic men than in non-Hispanic white men. The reasons behind these racial and ethnic differences are unclear.4

Compared with men in the US whose risk for prostate cancer is 17%, men who live in rural China have less risk (2%) of developing prostate cancer. Yet, the risk for prostate cancer increases for Chinese men if they move to a more western-style culture, reports the Prostate Cancer Foundation.2

According to the World Cancer Research Fund International, about 7 in 10 prostate cancer cases (72%) occur in more developed countries, with the highest rates of diagnosis in Australia and New Zealand, Western Europe, and North America.5

Sources
1. http://www.cancer.org/cancer/prostatecancer/detailed guide/prostate-cancer-key-statistics.
2. http://www.pcf.org/site/c.leJRIROrEpH/b.5802027/k.D271/Prostate_Cancer_Risk_Factors.htm.
3. http://www.pcf.org/site/c.leJRIROrEpH/b.8481037/k.1EF4/AfricanAmerican_Men__Risk_Factors.htm.
4. http://www.cancer.org/cancer/prostatecancer/detailed guide/prostate-cancer-risk-factors.
5. http://www.wcrf.org/cancer_statistics/data_specific_cancers/prostate_cancer_statistics.php.

Related Items
Investigational CAR T-Cell Therapy, bb2121, Shows Durable Responses in Relapsed or Refractory Multiple Myeloma
Wayne Kuznar
TON - November 2018, Vol 11, No 5 published on November 28, 2018 in Immunotherapy
High Tumor Microsatellite Instability a Marker for Lynch Syndrome, More Common Condition Than Generally Expected
Wayne Kuznar
TON - September 2018, Vol 11, No 4 published on September 19, 2018 in Lynch Syndrome
NCCN Updated Guideline Adds Treatment Options for HER2-Positive Breast Cancer, Emphasizing CDK4/CDK6 Inhibition in Hormone-Sensitive Disease
Wayne Kuznar
TOP Web Exclusives published on August 15, 2018 in NCCN News
NCCN Issues First Guideline for Immunotherapy-Related Adverse Events
Wayne Kuznar
JHOP Web Exclusives published on August 10, 2018 in Immunotherapy
Regorafenib Dose-Escalation Strategy Potentially a New Standard in Metastatic Colorectal Cancer
Wayne Kuznar
TOP - August 2018, Vol 11, No 2 published on August 3, 2018 in Colorectal Cancer
Immunotherapy Combination Shows Durable Responses in Mismatch Repair–Deficient Metastatic Colorectal Cancer
Wayne Kuznar
TOP - August 2018, Vol 11, No 2 published on August 3, 2018 in Immunotherapy
Noteworthy Numbers: Non-Hodgkin Lymphoma
TOP - August 2018, Vol 11, No 2 published on August 3, 2018 in Noteworthy Numbers
Noteworthy Numbers: Non-Hodgkin Lymphoma
TON - July 2018, Vol 11, No 3 published on July 25, 2018 in Noteworthy Numbers
Palliative Care Use Dismal Among Patients with Hematologic Malignancies
TON - March 2018, Vol 11, No 1 published on March 9, 2018 in Conference Correspondent, ASH, Palliative Care, Hematologic Cancers
Ivosidenib, New IDH1 Inhibitor, Elicits Complete Response in Relapsed Acute Myeloid Leukemia
Wayne Kuznar
TON - March 2018, Vol 11, No 1 published on March 9, 2018 in Conference Correspondent, Drug Updates & News, ASH
Last modified: May 21, 2015